These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 39393045)
1. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis. Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045 [TBL] [Abstract][Full Text] [Related]
2. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078 [TBL] [Abstract][Full Text] [Related]
3. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N; Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387 [TBL] [Abstract][Full Text] [Related]
4. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Butzkueven H; Kappos L; Spelman T; Trojano M; Wiendl H; Su R; Liao S; Hyde R; Licata S; Ho PR; Campbell N Ther Adv Neurol Disord; 2021; 14():17562864211042458. PubMed ID: 34603507 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392 [TBL] [Abstract][Full Text] [Related]
6. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Trojano M; Ramió-Torrentà L; Grimaldi LM; Lubetzki C; Schippling S; Evans KC; Ren Z; Muralidharan KK; Licata S; Gafson AR Mult Scler; 2021 Dec; 27(14):2240-2253. PubMed ID: 33821693 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Ghezzi A; Comi G; Grimaldi LM; Moiola L; Pozzilli C; Fantaccini S; Gallo P Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e591. PubMed ID: 31355324 [TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis. Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M; Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251 [TBL] [Abstract][Full Text] [Related]